Cifuentes, Ricardo A, Barreto, Emiliano · Biomedica : revista del Instituto Nacional de Salud · 2011 · DOI
This study examined whether specific genetic variations (single nucleotide polymorphisms or SNPs) could help predict who has ME/CFS. Researchers used a mathematical approach to identify the most useful genetic markers and found a combination of two genetic variants that correctly identified ME/CFS in about 73% of cases. When this genetic profile was combined with specific symptoms like muscle pain or sinus problems, the accuracy improved to over 87%.
This research addresses the challenge of identifying objective biomarkers for ME/CFS diagnosis, which currently relies on clinical criteria alone. A validated genetic profile could eventually support diagnostic accuracy and potentially enable stratification of patients into biologically meaningful subgroups for treatment. However, this represents early methodological work requiring validation in independent populations.
This study does not establish that these genetic variants cause ME/CFS or determine the biological mechanisms underlying the disease. The high accuracy reported reflects findings in a single dataset and requires prospective validation in independent cohorts before clinical utility can be assessed. Predictive accuracy in retrospective analysis does not directly translate to diagnostic utility in clinical practice.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →